#USA #New York #Pomerantz LLP #Keros Therapeutics #KROS

Pomerantz Law Firm Investigates Potential Claims Related to Keros Therapeutics

The Pomerantz Law Firm has initiated an investigation into claims surrounding Keros Therapeutics, Inc. (NASDAQ: KROS). This inquiry focuses on whether the company and its executives may have engaged in securities fraud or participated in questionable business practices that could have adversely impacted investors. Shareholders are encouraged to reach out for more information.

On December 12, 2024, Keros Therapeutics announced a significant development regarding its ongoing clinical trial for cibotercept (KER-012) aimed at treating pulmonary arterial hypertension (PAH). In a press release, the company disclosed a voluntary decision to halt dosing in specific treatment arms of the Phase 2 TROPOS trial. This action was taken after a safety review identified adverse events, specifically pericardial effusion, which were unexpected during the trial.

Following this alarming news, Keros's stock plummeted dramatically, experiencing a drop of $50.15 per share, translating to a staggering 73.05% decrease, closing at $18.50 on the same day. This sharp decline raised concerns among investors, prompting legal investigations into the possible implications of the company's announcement.

Pomerantz LLP, recognized as a leading firm specializing in corporate, securities, and antitrust class actions, aims to determine if Keros and its executives misled investors or failed to disclose critical information about the trial that could have influenced share prices. Having built a legacy over 85 years, Pomerantz continues to protect investors and recover substantial damages for those affected by corporate fraud and misconduct.

Investors who believe they may have been deceived or suffered losses due to Keros's actions are urged to contact the firm for potential participation in a class action lawsuit. The firm has a proven track record of holding companies accountable and securing restitution for victims of market manipulation and fraud.

For further inquiries, shareholders can reach out to Danielle Peyton from Pomerantz LLP via email at [email protected] or by phone at 646-581-9980, ext. 7980.

This investigation into Keros Therapeutics serves as a stark reminder of the vigilance required by investors in today's market environment. As companies navigate clinical trials and regulatory approvals, the responsibility to maintain transparency and trust with shareholders has never been more critical. The Pomerantz investigation will seek to clarify Keros’s accountability and uphold the rights of affected investors, ensuring they receive the justice they deserve.